| scholarly article | Q13442814 |
| P50 | author | Alison A Humbles | Q91272579 |
| Anthony J Coyle | Q96103239 | ||
| Roland Kolbeck | Q115616051 | ||
| Jennifer Kearley | Q115616054 | ||
| P2093 | author name string | Ronald Herbst | |
| Allison L Miller | |||
| Philip Brohawn | |||
| Ebony Benjamin | |||
| Gary P Sims | |||
| Ashley E Keller | |||
| Marlon C Rebelatto | |||
| Yambasu A Brewah | |||
| P2860 | cites work | Structural Basis for Ligand Recognition and Activation of RAGE | Q27665039 |
| HMGB1 and RAGE in inflammation and cancer | Q28274621 | ||
| Receptor for advanced glycation endproducts (RAGE) exhibits highly differential cellular and subcellular localisation in rat and human lung | Q28568578 | ||
| Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. | Q30378823 | ||
| Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. | Q30485791 | ||
| The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature | Q33298578 | ||
| The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. | Q33535780 | ||
| Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice | Q33558356 | ||
| Treatment of respiratory syncytial virus infection with recombinant interferon alfa-2a | Q33623939 | ||
| Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections | Q33911955 | ||
| CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection | Q34055489 | ||
| Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection | Q34072674 | ||
| Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice | Q34199969 | ||
| The burden of respiratory syncytial virus infection in young children | Q34938343 | ||
| NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus | Q34999264 | ||
| Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo | Q36098849 | ||
| sRAGE induces human monocyte survival and differentiation | Q36900801 | ||
| RSV infection in the adult population. | Q37355261 | ||
| Soluble forms of RAGE in human diseases: clinical and therapeutical implications | Q37411352 | ||
| DSCG reduces RSV-induced illness in RSV-infected mice | Q39310042 | ||
| Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response | Q40899986 | ||
| The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment | Q42037633 | ||
| Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection | Q43049804 | ||
| Viral etiology of acute exacerbations of COPD in Hong Kong. | Q43176140 | ||
| A 1-year prospective study of the infectious etiology in patients hospitalized with acute exacerbations of COPD. | Q43176495 | ||
| Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. | Q43633661 | ||
| Specific inhibition of type I interferon signal transduction by respiratory syncytial virus | Q43839646 | ||
| Interferon in nasal secretions from infants with viral respiratory tract infections | Q44022256 | ||
| RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. | Q44228474 | ||
| Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo | Q44837083 | ||
| Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation | Q45415295 | ||
| Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. | Q45420150 | ||
| Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases | Q45723031 | ||
| IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent | Q45738531 | ||
| In vivo production of tumour necrosis factor-alpha and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus | Q45780887 | ||
| Primary respiratory syncytial virus infection in mice | Q45833440 | ||
| Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. | Q46555270 | ||
| The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. | Q51758754 | ||
| Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. | Q53595048 | ||
| Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospectiv | Q62592896 | ||
| RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo | Q63916683 | ||
| Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene | Q73703121 | ||
| Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease | Q77220377 | ||
| Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1 | Q79390919 | ||
| sRAGE is elevated in septic patients and associated with patients outcome | Q81548751 | ||
| Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease | Q82117614 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1311-1320 | |
| P577 | publication date | 2012-01-18 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection | |
| P478 | volume | 205 |
| Q38541559 | Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung |
| Q35124150 | Clearance kinetics and matrix binding partners of the receptor for advanced glycation end products. |
| Q42248771 | RAGE inhibits human respiratory syncytial virus syncytium formation by interfering with F-protein function |
| Q27680115 | RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA |
| Q35112587 | S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo |
| Q59354444 | Serum soluble receptor for advanced glycation end-products during acute bronchiolitis in infant: Prospective study in 93 cases |
Search more.